CRISPR Therapeutics AG (CRSP)Healthcare | Biotechnology | Zug, Switzerland | NasdaqGM
51.52 USD
+1.30
(2.589%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:49 a.m. EDT
The long-term outlook remains neutral due to the company's status as a cash-burning biotech firm with no dividend and negative earnings, despite a recent year-over-year price surge. The business faces significant execution risk, and the lack of sustained profitability prevents a 'buy-and-hold' recommendation regardless of the recent price recovery. In the short term, the stock is a volatile speculation driven entirely by options flow targeting specific catalyst events. Traders are buying deep out-of-the-money calls for a moonshot move while holding protective puts nearby, creating a choppy trading environment where the statistical forecast offers no guidance. The disconnect between the high analyst target price and the negative fundamentals suggests the market is pricing in a potential miracle cure, but the current data supports a cautious stance. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.045060 |
| AutoETS | 0.045165 |
| AutoARIMA | 0.045178 |
| MSTL | 0.048851 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.50 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.546 |
| Excess Kurtosis | -0.79 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 44.874 |
| Revenue per Share | 0.141 |
| Market Cap | 4,981,605,888 |
| Forward P/E | -14.50 |
| Beta | 1.76 |
| Website | https://www.crisprtx.com |
As of Oct. 10, 2026, 3:49 a.m. EDT: Speculators are positioning for volatility rather than a clear directional breakout. Call volume is heavily skewed toward out-of-the-money strikes (60, 65, 75), indicating a speculative bet on a sharp rally, while put open interest clusters tightly around the current price (52-55), acting as a defensive floor. The massive implied volatility spikes at distant strikes suggest the market is pricing in binary event risk (clinical trial results or regulatory milestones) rather than steady price appreciation.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.25495303 |
| Address1 | Baarerstrasse 14 |
| All Time High | 220.2 |
| All Time Low | 11.63 |
| Ask | 67.84 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 2.1 - Buy |
| Average Daily Volume10 Day | 1,696,080 |
| Average Daily Volume3 Month | 1,581,315 |
| Average Volume | 1,581,315 |
| Average Volume10Days | 1,696,080 |
| Beta | 1.759 |
| Bid | 44.5 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 18.069 |
| City | Zug |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 51.52 |
| Current Ratio | 17.847 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 52.3725 |
| Day Low | 49.76 |
| Debt To Equity | 44.874 |
| Display Name | CRISPR Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -513,174,016 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.627 |
| Enterprise To Revenue | 253.958 |
| Enterprise Value | 3,401,001,472 |
| Eps Current Year | -4.4468 |
| Eps Forward | -3.55405 |
| Eps Trailing Twelve Months | -4.74 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 54.9916 |
| Fifty Day Average Change | -3.4715996 |
| Fifty Day Average Change Percent | -0.06312963 |
| Fifty Two Week Change Percent | -25.495302 |
| Fifty Two Week High | 75.06 |
| Fifty Two Week High Change | -23.539997 |
| Fifty Two Week High Change Percent | -0.31361574 |
| Fifty Two Week Low | 44.12 |
| Fifty Two Week Low Change | 7.4000015 |
| Fifty Two Week Low Change Percent | 0.16772443 |
| Fifty Two Week Range | 44.12 - 75.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,476,883,800,000 |
| Float Shares | 96,257,536 |
| Forward Eps | -3.55405 |
| Forward P E | -14.496139 |
| Free Cashflow | -215,845,872 |
| Full Exchange Name | NasdaqGM |
| Fullday Change | 0.40999985 |
| Fullday Change Percent | 0.7958071 |
| Fullday Price | 51.93 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -461,800,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0589 |
| Held Percent Institutions | 0.78218 |
| Implied Shares Outstanding | 96,692,653 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. |
| Long Name | CRISPR Therapeutics AG |
| Market | us_market |
| Market Cap | 4,981,605,888 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_262549448 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -451,139,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,391,582,331 |
| Number Of Analyst Opinions | 19 |
| Open | 49.98 |
| Operating Cashflow | -369,582,016 |
| Operating Margins | -11.27551 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 41 41 561 32 77 |
| Pre Market Change | 0.40999985 |
| Pre Market Change Percent | 0.7958071 |
| Pre Market Price | 51.93 |
| Pre Market Time | 1,792,152,928 |
| Previous Close | 50.22 |
| Price Eps Current Year | -11.585859 |
| Price Hint | 2 |
| Price To Book | 2.8512924 |
| Price To Sales Trailing12 Months | 371.9837 |
| Profit Margins | 0.0 |
| Quick Ratio | 17.791 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.08696 |
| Region | US |
| Regular Market Change | 1.3 |
| Regular Market Change Percent | 2.58861 |
| Regular Market Day High | 52.3725 |
| Regular Market Day Low | 49.76 |
| Regular Market Day Range | 49.76 - 52.3725 |
| Regular Market Open | 49.98 |
| Regular Market Previous Close | 50.22 |
| Regular Market Price | 51.52 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 1,351,476 |
| Return On Assets | -0.14204 |
| Return On Equity | -0.26095 |
| Revenue Growth | 10.414 |
| Revenue Per Share | 0.141 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 96,692,653 |
| Shares Percent Shares Out | 0.19319999 |
| Shares Short | 18,679,198 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 18,769,995 |
| Short Name | CRISPR Therapeutics AG |
| Short Percent Of Float | 0.2212 |
| Short Ratio | 11.76 |
| Source Interval | 15 |
| Symbol | CRSP |
| Target High Price | 291.0 |
| Target Low Price | 44.0 |
| Target Mean Price | 85.63158 |
| Target Median Price | 80.0 |
| Total Cash | 2,364,352,000 |
| Total Cash Per Share | 24.452 |
| Total Debt | 783,747,968 |
| Total Revenue | 13,392,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.74 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 53.132076 |
| Two Hundred Day Average Change | -1.6120758 |
| Two Hundred Day Average Change Percent | -0.030340916 |
| Type Disp | Equity |
| Volume | 1,351,476 |
| Website | https://www.crisprtx.com |
| Zip | 6,300 |